anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a composition containing the subject solid, entirely stable to heat and stable even in suspending in water by mixing crystals of midecamycin acetate which is a macrolide-based antibiotic substance with a specific additive and pulverizing the resultant mixture. CONSTITUTION:Crystals or crystalline powder of midecamycin acetate which is a macrolide-based antibiotic substance is mixed with an additive selected from synthetic polymers, cellulosic polymers and saccharides so that the amount of the additive may be 20-80% based on the total weight of the mixture. The resultant mixture is then pulverized until the midecamycin attains an amorphous substance. Furthermore, e.g. polyvinylpyrrolidone, methyl cellulose, dextrin, etc., are used as the afore-mentioned additive. For example, a vibrating ball mill, is used for the pulverization.
Uncontrolled hyperuricemia often leads to the development of hyperuricemic nephropathy (HN), characterized by excessive inflammation and oxidative stress. Piperine, a cinnamic acid alkaloid, possesses various pharmacological activities, such as antioxidant and anti-inflammatory effects. In this study, we intended to investigate the protective effects of piperine on adenine and potassium oxonate-induced HN mice and a uric-acid-induced injury model in renal tubular epithelial cells (mRTECs). We observed that treatment with piperine for 3 weeks significantly reduced serum uric acid levels and reversed kidney function impairment in mice with HN. Piperine (5 μM) alleviated uric acid-induced damage in mRTECs. Moreover, piperine inhibited transporter expression and dose-dependently inhibited the activity of both transporters. The results revealed that piperine regulated the AKT/mTOR signaling pathway both in vivo and in vitro. Overall, piperine inhibits URAT1/GLUT9 and ameliorates HN by inhibiting the AKT/mTOR pathway, making it a promising candidate for patients with HN.
Biliary tract complications are an important cause of morbidity and mortality after liver transplantation (LT) occurring in 5% to 25% of patients. The most common biliary complication in LT recipients are strictures representing approximately half of these biliary adverse events. Bile duct strictures can be divided into anastomotic biliary strictures (ABS) and non-anastomotic biliary strictures (NABS) depending on their location in the biliary tree, being ABS the most encountered type. Several risk factors identified in previous studies can predispose to the development of ABS and NABS, especially those related to surgical techniques and donor characteristics. Magnetic resonance cholangiopancreatography (MRCP) is the recommended noninvasive imaging test for detecting post-LT biliary strictures, given its high sensitivity and specificity. Once the diagnosis of a biliary stricture after LT has been made, endoscopic retrograde cholangiopancreatography (ERCP) is the preferred initial therapy with good short and long-term results. Biliary sphincterotomy plus balloon dilation (BD) with placement of multiple plastic stents (MPS) has been the classic endoscopic approach for treating ABS, although fully-covered metallic stents (FCSEMS) have emerged as an alternative thanks to shorter total duration of stenting and fewer endoscopic procedures compared to MPS. In this review, we provide a practical update on the management of biliary strictures after LT, focusing our attention on the available evidence in the endoscopic therapy.
PURPOSE:To obtain a skin cataplasm sheet excellent in usability and improved in the adhesive force between the sheet and tack agent, by providing a base sheet with a short fiber-incorporated primer layer followed by firmly laminating the primer layer with a tack agent layer. CONSTITUTION:Using, as a base sheet, a flexible vinyl chloride-based resin film 50-150mum thickness, one thereof is provided with (A) a primer layer containing 0.1-10wt.% of short fibers and consisting of a reaction product or mixture of a polyester resin having hydrophilic groups in the molecule and a polymerizable double bond-contg. monomer, followed by firmly laminating the primer layer with (B) a water-based tack agent layer by e.g. gravure coating method, thus obtaining the objective skin cataplasm sheet. Owing to the short fibers incorporated in the primer, unevennesses are developed on the surface of the primer sheet, expanding adhesive area through anchoring effect and raising the adhesive force between the base sheet and the tack agent. After this skin cataplasm sheet is used and peeled off the skin, nothing is left on the skin. This skin cataplasm sheet can also used in the form of a commerical product made up of a base sheet such as a protective sheet or electrical insulating tape and a tack agent layer.
Neurodynamic treatment for about 13 minutes in supine position. It will be comprised of three stages, and the tensioner technique of the tibial nerve will be used.
Hemorrhage is the chief complication that may result from heparin therapy (see WARNINGS). An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug (see OVERDOSAGE). It should be appreciated that gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:

(a) Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred during anticoagulant therapy. Therefore, such treatment should be discontinued in patients who develop signs and symptoms of acute adrenal hemorrhage and insufficiency. Initiation of corrective therapy should not depend on laboratory confirmation of the diagnosis, since any delay in an acute situation may result in the patient’s death.

(b) Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy. This complication, if unrecognized, may be fatal.

(c) Retroperitoneal hemorrhage.
###  Usual Initial Dosage

Paroxetine should be administered as a single daily dose with or without food, usually in the morning. In clinical trials the effectiveness of paroxetine was demonstrated in patients dosed in a range of 20 to 50 mg/day. The recommended starting dosage and the established effective dosage is 20 mg/day. There is not sufficient evidence to suggest a greater benefit to doses higher than 20 mg/day. Dose changes should occur in 10 mg/day increments and at intervals of at least 1 week. 

###  Maintenance Therapy

Systematic evaluation of continuing paroxetine for periods of up to 24 weeks in patients with Generalized Anxiety Disorder who had responded while taking paroxetine during an 8-week acute treatment phase has demonstrated a benefit of such maintenance (see CLINICAL PHARMACOLOGY, Clinical Trials). Nevertheless, patients should be periodically reassessed to determine the need for maintenance treatment.
Appendicitis in elderly patients is more challenging due to delayed presentation and higher comorbidities, which is associated with increased postoperative morbidity and mortality. In this study, we aim to investigate the factors that predict 30-day complications after the surgical treatment of appendicitis in elderly patients. Records of patients who underwent appendectomy for appendicitis will be extracted. The primary outcome is 30-day postoperative complications. Independent variables examined include demographics, comorbidities, preoperative laboratory values, pathological findings, and surgical features. Both univariate and multivariate regression will be performed to identify factors associated with postoperative complications.
Sepsis-induced acute lung injury (SI-ALI) leads to significant deaths in critically ill patients worldwide. This study explores the mechanism of EZH2 regulating ferroptosis of alveolar epithelial cells (AECs) in SI-ALI. In vitro cell model and in vivo mouse lung injury model of sepsis were established. EZH2 expression in lung tissues was intervened by sh-EZH2, followed by H&E staining observation of lung tissue pathological changes. EZH2, H3K27me3, USP10, GPX4, and ACSL4 expressions were determined by qRT-PCR or Western blot. ROS, GSH, and iron ion levels were detected using fluorescent labeling and reagent kits, respectively. ChIP analyzed the enrichment of EZH2 and H3K27me3 on USP10 promoter. The binding between USP10 and GPX4, and the ubiquitination level of GPX4 were detected using Co-IP. EZH2 was highly expressed in lung tissues of SI-ALI mice. EZH2 silencing alleviated ALI and ferroptosis of AECs; EZH2 increased the H3K27me3 level on USP10 promoter through histone methylation. USP10 stabilized GPX4 protein expression through ubiquitination; inhibition of USP10 partially reversed the inhibitory effect of EZH2 silencing on ferroptosis of AECs. In conclusion, EZH2 depresses USP10 expression by promoting histone H3K27me3 modification on USP10 promoter, thereby enhancing ubiquitination degradation of GPX4 and ultimately facilitating ferroptosis of AECs in sepsis.
In tropical countries, acute febrile illnesses represent a complex clinical problem for general practitioners. We describe the prevalence of different etiologies of acute febrile illnesses occurring among French service members and their families, excluding children, in general practice in French Guiana. From June 2017 to March 2020, patients with a fever ≥37.8°C with a duration of less than 15 days who sought medical care at the army medical centers in Cayenne and Kourou were prospectively enrolled. Based on clinical presentation, blood, urine, nasopharyngeal, and stool samples were collected for diagnostic testing for viruses, bacteria, and parasites (by direct examination, microscopic examination of blood smears, culture, serology, or polymerase chain reaction), and standardized biological tests were systematically performed. Among 175 patients retained for analysis, fever with nonspecific symptoms was predominant (46.9%), with 10 Plasmodium vivax malaria cases, 8 dengue infections, and 6 cases of Q fever. The second most frequent cause of acute febrile illness was upper respiratory tract infections (32.0%) due to influenza virus (n = 18) or human rhinovirus (n = 10). Among the causes of acute febrile illness in French Guiana, clinicians should first consider arboviruses and malaria, as well as Q fever in cases of elevated C-reactive protein with nonspecific symptoms and influenza in cases of signs and symptoms associated with upper respiratory tract infections. Despite an expanded microbiological search, the etiology of 51.4% of acute febrile illnesses remain unknown. Further investigations will be necessary to identify the etiology of acute febrile illnesses, including new pathogens, in French Guiana.
Trial design: A randomised non-inferiority controlled trial in primary care comparing facilitated access to a website for risky drinkers against a standard face-to-face BI. With the exception of the non-experimental intervention, all components of the study will be administered online to patients. Patients will be actively encouraged by their PHCP to access the application, which is available on the website of the programme 'Alcohol y Salud' (http:// www.alcoholysalud.cat), and will be provided with a unique registration code. The trial website is a Spanish adaptation of the English version of http://www.DownYourDrink.org.uk (DYD) developed in the UK, which includes modules for all the key trial components including screening, consent, assessment, randomisation and follow-up. It also incorporates the alcohol reduction website for the patients in the experimental group. The site has been adapted from the http://www.DownYourDrink.org.uk website developed for the DYD-RCT (randomised controlled trial).14 Details of DYD and the psychological theory that underpinned its development have been reported elsewhere. 21 Country-specific information such as recommended guidelines for alcohol intake, definitions of standard drinks and alcohol-related laws will be included. The website also incorporates a menu-driven facility to enable PHCP to customise automated messages to patients, for example, by adding photographs and pre-recorded messages. The personalised messages will appear to each patient using the log-in code provided by that practitioner.

Practitioner recruitment, training and incentives:

Recruitment will be based on the XaROH network. A 3 h seminar on new technologies, and EI and BI, introducing the trial, will be offered to all members of the XaROH, and those attending will be invited to sign up for the trial. In addition, several advertisements will be posted on the 'Beveu Menys' platform offering participation in the trial. In selecting practices, preference will be given to those with at least 5000 registered patients. Those practices that are selected as participants will be required to undergo a 1-day training programme. The training has four steps: (1) introduction to trial; (2) familiarisation with website; (3) update about EI and BI; and (4) practice in EI and BI (role-playing). Finally, participants will be encouraged to use the website and to tailor-make patient messages. Participating PHCPs will receive a financial incentive of €20 per patient recruited to the trial.
The  method  for   producing   a   controlled   release-type microcapsule is characterized by (a) adding an  aqueous  soln.  of water- soluble drug  and  diethylene  triamine  (or  tetraethylene pentamine) to an organic soln. of polyvinyl pyrrolidone surfactant and cebacoyl (or terephthaloyl  adipoyl,  isophthaloyl)  chloride, (b) agitating the mixed soln. to obtain a  polyamide  microcapsule by the interfacial polymerization, (c) coating the capsule with  a chloroform soln. contg. C12-18 fatty acid as an  organic  conating agent, and (d) drying the coated capsule.
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine preparation for treating subclinical hypothyroidism during a pregnancy period. It is considered in Chinese medicine science that the subclinical hypothyroidism during the pregnancy period is related to spleen and kidney deficiency, belongs to virtual consumptive disease categories of traditional Chinese medicine science and dialectically belongs to the syndromes of spleen-kidney-yang deficiency and phlegm-damp internal stagnation, and the spleen-kidney-yang deficiency particularly takes the kidney-yang deficiency as pathogenesis. According to the traditional Chinese medicine preparation, traditional Chinese medicines such as ballflower conehead, stems of bengal hiptage, tubers of satyrium henryi Schlecht., rhizomes of smilax perfoliata Lour., herba gynostemmatis pentaphylli, salix leaves, herb of oreas martiana (Hopp. et Hornsch.) Brid., petelot habenaria, fruit of common dysosma rhizomes and leaves cut from the parts, close to stems, in the centers of lotus leaves of nelumbo nucifera Gaertn. are selected carefully, the scientific formula is obtained according to theories of traditional Chinese medicines and raw material medicinal properties, the whole formula has the effects of nourishing yin, tonifying the kidney, calming the nerves, strengthening the spleen, tonifying qi, resolving phlegm, smoothing the liver, regulating qi and preventing miscarriage, both the symptoms and root causes of the subclinical hypothyroidism during the pregnancy period can be treated, the raditional Chinese medicine preparation has the advantages of being extract in curative effect, free of side effect and the like and is worthy of clinical popularization.
This is a single center, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis (AD). Thirty patients with moderate to severe AD will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 48). Improvement in patient quality of life after 52 weeks of treatment with dupilumab will be evaluated using validated dermatologic and non-dermatologic psychometric instruments. The primary endpoint is the improvement in quality of life measured by change in Psychological General Well-Being scale (PGWB) at Week 16 from baseline. Additionally, patients will be given a video recording device to document their experience with the study drug at home. Video footage of patient experiences will be compiled at the end of the study. The compiled video footage will subsequently be watched and analyzed to further understand the experiences of atopic dermatitis patients, and how undergoing dupilumab treatment alters these patients' experiences and attitudes with their skin disease.
Since 1975, the incidence of obesity has increased to epidemic proportions, and the number of patients with obesity has quadrupled. Obesity is a major risk factor for developing other serious diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Recent epidemiologic studies have defined obesity as a risk factor for the development of neurodegenerative diseases, such as Alzheimer's disease (AD) and other types of dementia. Despite all these serious comorbidities associated with obesity, there is still a lack of effective antiobesity treatment. Promising candidates for the treatment of obesity are anorexigenic neuropeptides, which are peptides produced by neurons in brain areas implicated in food intake regulation, such as the hypothalamus or the brainstem. These peptides efficiently reduce food intake and body weight. Moreover, because of the proven interconnection between obesity and the risk of developing AD, the potential neuroprotective effects of these two agents in animal models of neurodegeneration have been examined. The objective of this review was to explore anorexigenic neuropeptides produced and acting within the brain, emphasizing their potential not only for the treatment of obesity but also for the treatment of neurodegenerative disorders.
The present invention provides the synthesis method for 1 - alkyl 2 - (4 - Beta-D-glucoside alor - phenyl) - benzimidazole derivatives, and discloses a preparation method for bean-curd fruit derivatives that can improve the central nervous system. The compounds are of good sedative, hypnotic and anticonvulsant effects. At present, the product is included in the Chinese Pharmacopoeia of the 2000-year version under the name of ''Nervous-evoking Fruit Pill''. The bean-curd fruit derivative has the chemical formulas (I) and (II). The bean-curd fruit derivatives provided in the present invention are compounds which take plant active monomers bean-curd fruits that are of sedative, hypnotic and anticonvulsant effects as the matrixes. The structure of the present invention is improved and designed under the principles of drug structure molecular. The present invention is compound which can improve the central nervous system and is of high activity.
Spinal cord injury (SCI) is a significant contributor to disability in contemporary society, resulting in substantial psychological and economic burdens for patients and their family. Microglia-mediated inflammation is an important factor affecting the nerve repair of SCI patients. N6-methyladenosine (m6A) is a prevalent epigenetic modification in mammals, which shows a strong association with inflammation. However, the mechanism of m6A modification regulating microglia-mediated inflammation is still unclear. Here, we observed that METTL3, a m6A methylase, was increased in SCI mice and lipopolysaccharide (LPS)-exposed BV2 cells. Knockdown of METTL3 inhibited the increased expression of iNOS and IL-1β induced by LPS in vitro. Subsequently, MEF2C, myocyte-specific enhancer factor 2C, was decreased in SCI mice and LPS-exposed BV2 cells. Knockdown of MEF2C promoted the expression of iNOS and IL-1β. Sequence analysis showed that there were multiple highly confident m6A modification sites on the MEF2C mRNA. METTL3 antibody could pull down a higher level of MEF2C mRNA than the IgG in RNA binding protein immunoprecipitation assay. Knockdown of METTL3 promoted MEF2C protein expression and MEF2C mRNA expression, accompanied by a reduced m6A modification level on the MEF2C mRNA. Knockdown of MEF2C inhibited the anti-inflammatory effect of METTL3 siRNA. Our results suggest that METTL3 promotes microglia inflammation via regulating MEF2C mRNA m6A modification induced by SCI and LPS treatment.
The present application describes a ceddna vector with a linear continuous structure for delivery and expression of transgenes. The ceDNA vector comprises an expression cassette flanked by two ITR sequences, wherein the expression cassette encodes a transgene. Some ceddna vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable in vitro, ex vivo and in vivo gene expression using the ceddna vectors. Provided herein are methods and compositions comprising a ceddna vector suitable for expressing an antibody or fusion protein in a cell, tissue, or subject. Such antibodies or fusion proteins can be expressed for use in treating disease, or alternatively for producing antibodies or fusion proteins in a commercial setting.
Cutaneous larva migrans (CLM), commonly referred to as creeping eruption, is an infectious condition caused by various types of hookworms. It primarily affects the superficial layers of the skin owing to the absence of hyaluronidases and proteases. Typically, the distal lower extremities are the most commonly affected areas. The presence of distinctive lesions characterized by erythematous, winding, or serpentine tracks, slightly elevated from the skin surface, is indicative of the condition. Diagnosis primarily relies on clinical observation. Dermoscopy reveals multiple segmented yellowish-linear regions corresponding to pustules along the larval path. Treatment typically involves the use of topical and oral ivermectin, oral albendazole, and topical thiabendazole cream.
An integrated machine-to-machine mobile health gateway communications device for diabetes remote monitoring is described. The communications device 30 is connectable to a plurality of different types of glucose meter 20 and the Internet. The device comprises a controller, a first communications interface for connecting to a glucose meter, the glucose meter being one of a plurality of different types of glucose meter to which the first communications interface can connect, and receiving blood glucose measurements from the connected glucose meter, a second communications interface 70 for connecting to the Internet and transmitting the received blood glucose measurements over the Internet to a remote server, a battery, for powering the medical communications device, and a motion sensor. The controller is operable to activate the communications device in response to the motion sensor detecting movement of the communications device. Other embodiments provide for intelligent selection of a communications channel for use by the second communications interface through the use of different communications protocols. In embodiments, the device may also connect to the internet through different first and second communications channels, the second can be selectively used when the first is unable to connect.